Type 2 & other diabetes

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin

Diabetes Obes MetabPublished Randomised controlled trial

Primary result · HbA1cResult — go to the resultCorrected mean difference −0.42 %

Authors' conclusion

Adjunctive pioglitazone treatment in T2DM inadequately controlled with metformin and dapagliflozin demonstrates considerable glycaemic improvement, metabolic benefits, and a low risk of hypoglycaemia. These advantages must be weighed against the potential for weight gain and increased waist circumference.

Study context

Population
Korean patients with T2D suboptimally managed on metformin and dapagliflozin
Participants
249 patients
Comparison
Pioglitazone 15 mg daily vs placebo added to metformin plus dapagliflozin
Primary endpoint
Change in HbA1c
Follow-up
24 weeks
Methodological detailsmulticentre, double-blind, placebo-controlled, 24-week pioglitazone extension
  • Multicentre
  • Double-blind
  • Placebo-controlled
  • 24-week pioglitazone extension

Primary result

HbA1c

Corrected mean difference

−0.42 %

P < 0.01

By group

As reported in the abstract

Secondary outcomes

Pioglitazone enhanced insulin sensitivity, increased adiponectin, raised HDL-C and reduced liver enzymes, improving NAFLD liver fat score

Safety

Events

OutcomePioglitazonePlacebo
Serious adverse events, weight and waist circumference00

Serious adverse events, weight and waist circumference

No serious adverse events in either group
Pioglitazone modestly but significantly associated with weight gain and increased waist circumference

Original publication

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diabetes Obes Metab. Published 29 February 2024. doi:10.1111/dom.15526

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.